Levy Yifat Amir, Mausner-Fainberg Karin, Vaknin-Dembinsky Adi, Amidror Tali, Regev Keren, Karni Arnon
Neuroimmunology Laboratory, Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
J Neuroimmunol. 2015 Jan 15;278:85-9. doi: 10.1016/j.jneuroim.2014.12.010. Epub 2014 Dec 10.
Leukemia inhibitory factor (LIF) is known to potentiate the differentiation and survival of neuronal and oligodendrocyte precursors. Systemic therapy with LIF reportedly ameliorated the severity of experimental autoimmune encephalomyelitis and prevented oligodendrocyte death. We studied the secreted LIF levels from immune cells of relapsing remitting multiple sclerosis (RR-MS) patients compared to age- and gender-matched healthy controls (HCs). LIF was barely detected in the supernatants when the cells were not stimulated. After stimulation with anti-CD3/CD28 monoclonal antibody, LIF levels were up-regulated in both patients and controls, although to a significantly lower extent in RR-MS patients compared to HC. There were no significant differences between untreated patients and interferon-β1a treated patients. This is a heretofore unreported aspect of immune dysregulation in patients with RR-MS that may be related to insufficient remyelination and neurogenesis in MS lesions.
已知白血病抑制因子（LIF）可增强神经元和少突胶质细胞前体的分化与存活。据报道，用LIF进行全身治疗可改善实验性自身免疫性脑脊髓炎的严重程度，并防止少突胶质细胞死亡。我们研究了复发缓解型多发性硬化症（RR-MS）患者与年龄和性别匹配的健康对照（HC）的免疫细胞分泌的LIF水平。当细胞未受刺激时，上清液中几乎检测不到LIF。用抗CD3/CD28单克隆抗体刺激后，患者和对照的LIF水平均上调，尽管与HC相比，RR-MS患者的上调程度明显较低。未经治疗的患者与接受干扰素-β1a治疗的患者之间无显著差异。这是RR-MS患者免疫失调方面迄今未报道的一个方面，可能与MS病变中髓鞘再生不足和神经发生有关。
